{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:32:35Z","timestamp":1761514355956,"version":"build-2065373602"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.berh.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T09:24:14Z","timestamp":1551518654000},"page":"427-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disease modification in axial spondyloarthritis"],"prefix":"10.1016","volume":"32","author":[{"given":"Ismail","family":"Sari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2019.02.007_bib1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/acr.22730","article-title":"Work outcome in patients with ankylosing spondylitis: results from a 12-year followup of an international study","volume":"68","author":"Castillo-Ortiz","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2019.02.007_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.berh.2010.05.005","article-title":"Are current available therapies disease-modifying in spondyloarthritis?","volume":"24","author":"Lories","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10067-015-2956-4","article-title":"Ankylosis in ankylosing spondylitis: current concepts","volume":"34","author":"Haroon","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2009.258","article-title":"Disease modification in ankylosing spondylitis","volume":"6","author":"Maksymowych","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12659\/MSMBR.901142","article-title":"Osteoblast differentiation at a glance","volume":"22","author":"Rutkovskiy","year":"2016","journal-title":"Med Sci Monit Basic Res"},{"key":"10.1016\/j.berh.2019.02.007_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/978-1-4419-0298-6_8","article-title":"Bone formation versus bone resorption in ankylosing spondylitis","volume":"649","author":"Schett","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.berh.2019.02.007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8515-6","article-title":"Bone as a target organ in rheumatic disease: impact on osteoclasts and osteoblasts","volume":"51","author":"Baum","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2019.02.007_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.10.013","article-title":"Mediators of inflammation and bone remodeling in rheumatic disease","volume":"49","author":"Shaw","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.berh.2019.02.007_bib11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jbspin.2015.07.008","article-title":"Molecular mechanisms of bone formation in spondyloarthritis","volume":"83","author":"Gonzalez-Chavez","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2019.02.007_bib12","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI23738","article-title":"Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis","volume":"115","author":"Lories","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.berh.2019.02.007_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/03009740701774941","article-title":"Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis","volume":"37","author":"Park","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib14","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3899\/jrheum.100200","article-title":"Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis","volume":"37","author":"Chen","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104966","article-title":"Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis","volume":"9","author":"Joo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2019.02.007_bib16","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/annrheumdis-2013-203630","article-title":"Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis","volume":"73","author":"Tsui","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2019.02.007_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ard.2008.102046","article-title":"Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints","volume":"69","author":"Uderhardt","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.27231","article-title":"Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis","volume":"62","author":"Daoussis","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","article-title":"High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis","volume":"71","author":"Heiland","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib21","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1186\/ar4096","article-title":"Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors","volume":"14","author":"Haynes","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.02.007_bib22","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","article-title":"Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis","volume":"60","author":"Appel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fimmu.2014.00048","article-title":"Classical and paradoxical effects of TNF-alpha on bone homeostasis","volume":"5","author":"Osta","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2019.02.007_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar2135","article-title":"Bone morphogenetic proteins in destructive and remodeling arthritis","volume":"9","author":"Lories","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.02.007_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2013.07.016","article-title":"Inflammatory pathways in spondyloarthritis","volume":"57","author":"Hreggvidsdottir","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.berh.2019.02.007_bib26","doi-asserted-by":"crossref","first-page":"2403935","DOI":"10.1155\/2018\/2403935","article-title":"Role of interleukin- (IL-) 17 in the pathogenesis and targeted therapies in spondyloarthropathies","volume":"2018","author":"Chyuan","year":"2018","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.berh.2019.02.007_bib27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gamma t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2019.02.007_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/08916934.2014.976630","article-title":"Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice","volume":"48","author":"Ebihara","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.berh.2019.02.007_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","article-title":"Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation","volume":"60","author":"Maksymowych","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2642","article-title":"Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis","volume":"11","author":"Lories","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.02.007_bib31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.berh.2014.10.008","article-title":"Bone formation in axial spondyloarthritis","volume":"28","author":"Lories","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.2004.020503","article-title":"Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system","volume":"64","author":"Creemers","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib35","first-page":"125","article-title":"Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years","volume":"31","author":"Spoorenberg","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib36","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib37","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.080871","article-title":"The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients","volume":"36","author":"Baraliakos","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11926-011-0192-8","article-title":"The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features","volume":"13","author":"Baraliakos","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2019.02.007_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/annrheumdis-2011-200411","article-title":"Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study","volume":"71","author":"van Tubergen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib43","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib44","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3906\/sag-1401-79","article-title":"Treatment of ankylosing spondylitis","volume":"45","author":"Sari","year":"2015","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.berh.2019.02.007_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010952.pub2","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)","author":"Kroon","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2019.02.007_bib47","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/annrheumdis-2012-201844","article-title":"NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms?","volume":"71","author":"Haroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib48","first-page":"60","article-title":"Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone","volume":"5","author":"Boersma","year":"1976","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib49","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib50","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib51","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib52","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib53","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib54","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/rheumatology\/kei046","article-title":"Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab","volume":"44","author":"Sieper","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.02.007_bib55","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3899\/jrheum.091043","article-title":"Low-dose infliximab (3 mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study","volume":"37","author":"Maksymowych","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib56","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/ard.2004.033472","article-title":"Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab","volume":"64","author":"Baraliakos","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib57","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib58","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/rheumatology\/keu263","article-title":"Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial","volume":"54","author":"Song","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.02.007_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib62","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","article-title":"Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib63","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/annrheumdis-2015-208011","article-title":"MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis","volume":"75","author":"Machado","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib64","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.100925","article-title":"Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation","volume":"38","author":"Pedersen","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib66","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acr.23097","article-title":"Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors","volume":"69","author":"Maas","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.02.007_bib67","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib68","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jbspin.2015.09.006","article-title":"Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: observation Study of Korean Spondyloarthropathy Registry (OSKAR) data","volume":"83","author":"Kim","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2019.02.007_bib69","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib70","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib71","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.02.007_bib72","article-title":"What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both?","author":"Poddubnyy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.02.007_bib73","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"journal-title":"Arthritis Rheum","year":"2018","author":"Deodhar","key":"10.1016\/j.berh.2019.02.007_bib74"},{"key":"10.1016\/j.berh.2019.02.007_bib75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib76","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2019.02.007_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","article-title":"Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study","volume":"75","author":"Baraliakos","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib78","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2018-eular.1396","article-title":"SAT0268 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis","volume":"77","author":"Baraliakos","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02208032","article-title":"Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment","volume":"10","author":"Taylor","year":"1991","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000153","article-title":"Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2019.02.007_bib81","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/acr.23157","article-title":"Disease severity in never smokers, ex-smokers, and current smokers with axial spondyloarthritis: results from the scotland registry for ankylosing spondylitis","volume":"69","author":"Jones","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2019.02.007_bib82","first-page":"1420","article-title":"Predictors of the progression of functional disability in patients with ankylosing spondylitis","volume":"29","author":"Ward","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.02.007_bib83","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/annrheumdis-2013-205133","article-title":"Impaired response to treatment with tumour necrosis factor alpha inhibitors in smokers with axial spondyloarthritis","volume":"75","author":"Ciurea","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib84","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.semarthrit.2016.11.004","article-title":"The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: a systematic literature review","volume":"46","author":"Villaverde-Garcia","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.02.007_bib85","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/eci.13.35","article-title":"Spondyloarthritis and smoking: towards a new insight into the disease","volume":"9","author":"Wendling","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.berh.2019.02.007_bib86","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib87","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.02.007_bib88","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:18:31Z","timestamp":1761499111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521694219300294"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.02.007","relation":{},"ISSN":["1521-6942"],"issn-type":[{"type":"print","value":"1521-6942"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease modification in axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}